Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia

Juha Rasanen, Matthew J. Quinn, Amber Laurie, Eric Bean, Charles Roberts, Srinivasa R. Nagalla, Michael G. Gravett

Research output: Contribution to journalArticle

19 Scopus citations


Objective We assessed the association of glycosylated fibronectin (GlyFn) with preeclampsia and its performance in a point-of-care (POC) test.

Study Design GlyFn, placental growth factor (PlGF), and soluble vascular endothelial growth factor receptor 1 (sFlt1) levels were determined in serum samples from 107 pregnant women. In all, 45 were normotensive and 62 were diagnosed with preeclampsia. The ability of GlyFn to assess preeclampsia status and relationships between GlyFn and maternal characteristics and pregnancy outcomes were analyzed.

Results GlyFn serum levels in the first trimester were significantly higher in women with preeclampsia (P

Conclusion GlyFn is a robust biomarker for monitoring of preeclampsia in both a standard and POC format, which supports its utility in diverse settings.

Original languageEnglish (US)
Pages (from-to)82.e1-82e9
JournalAmerican Journal of Obstetrics and Gynecology
Issue number1
Publication statusPublished - Jan 1 2015



  • biomarker
  • glycosylated fibronectin
  • point-of-care
  • preeclampsia

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this